Pharvaris N.V. (NASDAQ:PHVS) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Fourteen brokerages rate Pharvaris an overall "Moderate Buy" (11 buys, 2 holds, 1 sell) with a 12‑month average price target of $42.73.
• Financials: Pharvaris reported Q1 EPS of ($0.84), missing estimates by $0.15 and analysts forecast roughly -$3.19 EPS for the year; shares trade near $29.44 with a market cap of about $1.93B.
• Insider activity: Insiders sold 150,659 shares (~$4.49M) in the last three months—including notable sales by Johannes Schikan, Anne Lesage and Peng Lu—though insiders still own about 11.84% of the stock.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $42.7273.

Several equities research analysts recently commented on PHVS shares. Wall Street Zen downgraded Pharvaris from a "sell" rating to a "strong sell" rating in a report on Monday, April 13th. HC Wainwright reiterated a "buy" rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Wedbush raised their target price on Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday, April 7th. Citigroup reiterated a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They set an "outperform" rating and a $42.00 target price on the stock.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $29.44 on Friday. The company has a market cap of $1.93 billion, a P/E ratio of -8.74 and a beta of -2.34. Pharvaris has a one year low of $14.59 and a one year high of $31.14. The business's 50-day simple moving average is $27.62 and its 200 day simple moving average is $26.03.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Analysts predict that Pharvaris will post -3.19 earnings per share for the current year.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Insiders Place Their Bets

In other Pharvaris news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40. Following the sale, the director directly owned 355,167 shares in the company, valued at $10,768,663.44. The trade was a 7.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anne Lesage sold 19,200 shares of Pharvaris stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $30.26, for a total value of $580,992.00. Following the sale, the insider owned 133,969 shares in the company, valued at $4,053,901.94. This represents a 12.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 150,659 shares of company stock worth $4,489,587 in the last three months. 11.84% of the stock is owned by insiders.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL purchased a new stake in Pharvaris during the 3rd quarter worth approximately $1,943,000. Patient Square Capital LP increased its holdings in Pharvaris by 41.4% during the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company's stock worth $8,617,000 after purchasing an additional 101,098 shares during the last quarter. Boothbay Fund Management LLC increased its holdings in Pharvaris by 735.1% during the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company's stock worth $3,373,000 after purchasing an additional 118,994 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Pharvaris by 710.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company's stock worth $676,000 after purchasing an additional 23,743 shares during the last quarter. Finally, General Atlantic L.P. increased its holdings in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock worth $200,380,000 after purchasing an additional 500,000 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.